INT178488

From wiki-pain
Revision as of 05:20, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.08
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 10
Disease Relevance 6.18
Pain Relevance 0.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Aggf1) extracellular region (Aggf1) cell adhesion (Aggf1)
intracellular (Aggf1) cytoplasm (Aggf1)
Anatomy Link Frequency
endothelial cells 4
endothelium 1
Aggf1 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 45 99.96 Very High Very High Very High
Inflammation 80 94.80 High High
metalloproteinase 70 88.24 High High
ketamine 1 32.08 Quite Low
anesthesia 7 11.04 Low Low
fibrosis 38 5.00 Very Low Very Low Very Low
Inflammatory response 13 5.00 Very Low Very Low Very Low
imagery 13 5.00 Very Low Very Low Very Low
alcohol 10 5.00 Very Low Very Low Very Low
Potency 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 588 99.84 Very High Very High Very High
Lymphatic System Cancer 188 98.70 Very High Very High Very High
Apoptosis 68 97.92 Very High Very High Very High
INFLAMMATION 90 94.80 High High
Metastasis 84 93.04 High High
Bladder Cancer 1 91.24 High High
Leukemia 3 90.24 High High
Severe Combined Immunodeficiency 46 89.68 High High
Colon Cancer 32 89.56 High High
Hepatitis 1 88.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Preparation of PEG-PEI-ESO polyplexes
Localization (Preparation) of PEG
1) Confidence 0.08 Published 2008 Journal BMC Biotechnol Section Body Doc Link PMC2362111 Disease Relevance 0 Pain Relevance 0
During this experiment, we recorded proteasome inhibitory activity (Relative Luminescence Units, RLU) of room temperature incubated PLGA-PEGPS341- and DSPE-PEGPS341- (control, non-PLGA) nanoparticles for day 1 to 7 and observed sustained release of PS341 from PLGA-PEG (Fig 2B).
Localization (release) of PEG
2) Confidence 0.04 Published 2010 Journal J Nanobiotechnology Section Body Doc Link PMC2954907 Disease Relevance 0 Pain Relevance 0
We quantified the release kinetics of PS-341 from PLGA-PEG in resuspension buffer (PBS, 100 ?
Localization (release) of PEG
3) Confidence 0.04 Published 2010 Journal J Nanobiotechnology Section Body Doc Link PMC2954907 Disease Relevance 0 Pain Relevance 0
Our data indicate that THL not only could inhibit the migration, invasion, and tube formation ability of endothelial cells but also could inhibit cancer cells to secrete the pro-angiogenic factor VEGF-A.
Localization (secrete) of pro-angiogenic factor in endothelial cells associated with cancer
4) Confidence 0.02 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2880989 Disease Relevance 1.60 Pain Relevance 0
Secondly, THL could inhibit the secretion of pro-angiogenic factor by cancer cells (Fig 7).
Localization (secretion) of pro-angiogenic factor associated with cancer
5) Confidence 0.02 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2880989 Disease Relevance 1.01 Pain Relevance 0.07
One mechanism by which the IFN may exhibit this action is by downregulation of pro-angiogenic factors secreted by the tumor cell [91].
Localization (secreted) of pro-angiogenic associated with cancer
6) Confidence 0.02 Published 2004 Journal J Transl Med Section Body Doc Link PMC455695 Disease Relevance 1.13 Pain Relevance 0.03
Thus, although we were unable to document the relevance of these in vitro data in our animal models, our findings suggest the existence of a complex interplay between MSC, lymphoma cells and endothelial cells, characterized by: i) a significant release of pro-angiogenic/pro-migratory cytokines by MSC, which is enhanced by the presence of lymphoma cells; ii) a potent chemotactic activity of MSC on endothelial cells, followed by a cytotoxic activity of MSC on endothelial cells, which required the MSC/endothelial cell contact.
Localization (release) of pro-angiogenic in endothelial cell associated with lymphatic system cancer and cytokine
7) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2886845 Disease Relevance 0.54 Pain Relevance 0.12
Since MSC release a cocktail of potent pro-angiogenic factors [28]–[30], we have next examined the ability of MSC to drive the migration of endothelial cells.
Localization (release) of pro-angiogenic in endothelial cells
8) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2886845 Disease Relevance 0.29 Pain Relevance 0.10
Consistently with their ability of release several pro-angiogenic cytokines, MSC potently promoted the migration of endothelial cells in transwell assays.
Localization (release) of pro-angiogenic in endothelial cells associated with cytokine
9) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2886845 Disease Relevance 0.74 Pain Relevance 0.10
An inactive endothelium will sequester fewer leukocytes and will secrete reduced levels of pro-angiogenic factors.(11)
Localization (secrete) of pro-angiogenic in endothelium
10) Confidence 0.01 Published 2008 Journal Biomarker Insights Section Body Doc Link PMC2600574 Disease Relevance 0.88 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox